Assorted News from the Last Week: On September 26, 2023, the FDA approved bosutinib (Bosulif, Pfizer) for pediatric patients 1 year of age and older

Assorted News from the Last Week: U.S. Congressman Michael McCaul (R-Texas) and Childhood Cancer Caucus Co-Chairs Ami Bera (D-Calif.) and Mike Kelly (R-Pa.) introduced the

Assorted News from the Last Week: White House announces new Cancer Moonshot Initiatives, including several initiatives involving CAC2 Members: xCures, a health-data technology platform, is

Assorted News from the Last Week: A retrospective study shows that more intense ALL therapy improves outcomes in adolescents and young adults. This treatment option

Assorted News from the Last Week: Major League Soccer, MLS WORKS – the League’s social responsibility platform – and Continental Tire are teaming up during

Assorted News from the Last Week: Despite major advances in cancer research, we collectively fall short in bringing innovative medicines to children with cancer.  A

Assorted News from the Last Two Weeks: Latino children are at greater risk of developing certain cancers, and their short and long-term outcomes are often

Assorted News from the Last Week: High-Throughput drug screening of primary tumor cells identifies therapeutic strategies for treating children with high-risk cancer. Tribute to CAC2

Assorted News from the Last Week: The Senate Appropriations Committee has released its Fiscal Year 2024 Labor-HHS Appropriations bill, and we are excited to report that

Assorted News from the Last Week: A Danish study shows that five-year survival of all children with acute lymphatic leukemia (ALL) has continued to increase